Results 1 to 10 of about 47,410 (185)

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines [PDF]

Molecular Cancer, 2011
Background YB-1 is a multifunctional protein that affects transcription, splicing, and translation. Overexpression of YB-1 in breast cancers causes cisplatin resistance. Recent data have shown that YB-1 is also overexpress in colorectal cancer.
Tsofack Serges P, Garand Chantal, Sereduk Chris, Chow Donald, Aziz Meraj, Guay David, Yin Hongwei H, Lebel Michel   +7 more
doaj   +5 more sources

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. [PDF]

PLoS ONE, 2017
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell line
Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis   +39 more
doaj   +19 more sources

USF1-activated hsa_circ_0076691 induces oxaliplatin resistance via facilitating FGF9 expression in miR-589-3p-dependent manners [PDF]

Non-coding RNA Research
Chemotherapeutic efficacy in colorectal cancer (CRC) is significantly hindered by the development of drug resistance. Emerging evidence indicates that circular RNAs (circRNAs) play pivotal roles in various cancer-related biological processes. Nonetheless,
Lingyu Tang, Xuan Deng, Ming Guan, Liang Zhong   +3 more
doaj   +3 more sources

Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer [PDF]

Scientific Reports
Oxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang, Ruizhe Zhang, Shuang He, Feifei Wen, Xiaojie Yu, Xiaoyang Xu, Yangyang Li, Shuhua Wu   +7 more
doaj   +2 more sources

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells [PDF]

, 2016
Oxaliplatin resistance in colorectal cancers (CRC) is a major medical problem, and predictive markers are urgently needed. Recently, miR-625-3p was reported as a promising predictive marker.
Andersen, Claus Lindbjerg, Hansen, Flemming, Hansen, Tine Plato, Jersie-Christensen, Rosa Rakownikow, Lyskjær, Iben, Nielsen, Morten Muhlig, Olsen, Jesper Velgaard, Pedersen, Jakob Skou, Pfeiffer, Per, Primdal-Bengtson, Bjarke, Rasmussen, Mads Heilskov, Tarpgaard, Line Schmidt, Ørntoft, Torben Falck   +12 more
core   +5 more sources

Alteration of chromatin high‐order conformation associated with oxaliplatin resistance acquisition in colorectal cancer cells

Exploration, 2023
Oxaliplatin is a first‐line chemotherapy drug widely adopted in colorectal cancer (CRC) treatment. However, a large proportion of patients tend to become resistant to oxaliplatin, causing chemotherapy to fail.
Peilong Li, Xueying Shang, Qinlian Jiao, Qi Mi, Mengqian Zhu, Yidan Ren, Juan Li, Li Li, Jin Liu, Chuanxin Wang, Yi Shi, Yunshan Wang, Lutao Du   +12 more
doaj   +2 more sources

UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer [PDF]

Communications Biology
Stress granules (SGs), which are phase-separating organelles that serve as protective cellular mechanisms in response to various harmful stimuli, have an unclear role in oxaliplatin resistance.
Chaorui Wu, Yu Yan, Qichen Chen, Zhiying Lian, Jiayong He, Ruoyu Ling, Xuetao Lei, Yanmei Peng, Boyang Zheng, Qingbin Yang, Gengtai Ye, Wenhui Ma, Guoxin Li   +12 more
doaj   +2 more sources

PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer [PDF]

Nature Communications, 2023
Despite being an effective treatment for hepatocellular carcinoma (HCC), resistance to oxaliplatin presents a major obstacle. Here, the authors identify PRMT3-induced methylation of IGF2BP1 resulting in HEG1 stabilisation as a mechanism of oxaliplatin ...
Yunxing Shi, Yi Niu, Yichuan Yuan, Kai Li, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Wei He, Chenwei Wang, Yadi Liao, Guocan Wang, Yunfei Yuan, Binkui Li   +16 more
doaj   +2 more sources

Influence of Citrobacter freundii on NINJ2 Expression and Oxaliplatin Resistance in Colorectal Cancer [PDF]

Cancer Medicine
Background Oxaliplatin, a third‐generation platinum‐based chemotherapeutic agent, is widely used in the treatment of colorectal cancer (CRC). However, some patients do not respond effectively to oxaliplatin, and intrinsic resistance to the drug poses a ...
Reio Ueta, Hiroo Imai, Ken Saijo, Yoshifumi Kawamura, Shuto Kodera, Chikashi Ishioka   +5 more
doaj   +2 more sources

The Role and Mechanism of Innate Immune Regulation in Overcoming Oxaliplatin Resistance and Enhancing Anti-Tumor Efficacy in Colorectal Cancer [PDF]

Pharmaceuticals
Background/Objectives: The reversal effect of cGAMP, as a STING pathway regulator, on oxaliplatin resistance in colorectal cancer was investigated, and its mechanism was proposed.
Xiaoqing Wang, Meili Xi, Xing Lu, Xiangshi Tan   +3 more
doaj   +2 more sources